234 related articles for article (PubMed ID: 29388023)
1. Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro.
Jung J; Park JS; Righesso L; Pabst AM; Al-Nawas B; Kwon YD; Walter C
Clin Oral Investig; 2018 Sep; 22(7):2527-2534. PubMed ID: 29388023
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.
Walter C; Pabst A; Ziebart T; Klein M; Al-Nawas B
Oral Dis; 2011 Mar; 17(2):194-9. PubMed ID: 20796232
[TBL] [Abstract][Full Text] [Related]
3. Geranyl-geraniol addition affects potency of bisphosphonates-a comparison in vitro promising a therapeutic approach for bisphosphonate-associated osteonecrosis of the jaw and oral wound healing.
Otto M; Lux C; Schlittenbauer T; Halling F; Ziebart T
Oral Maxillofac Surg; 2022 Jun; 26(2):321-332. PubMed ID: 34392434
[TBL] [Abstract][Full Text] [Related]
4. The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.
Pabst AM; Ziebart T; Koch FP; Taylor KY; Al-Nawas B; Walter C
Clin Oral Investig; 2012 Feb; 16(1):87-93. PubMed ID: 21225298
[TBL] [Abstract][Full Text] [Related]
5. Impact of bisphosphonates on the proliferation and gene expression of human fibroblasts.
Manzano-Moreno FJ; Illescas-Montes R; Melguizo-Rodriguez L; Costela-Ruiz VJ; García-Martínez O; Ruiz C; Ramos-Torrecillas J
Int J Med Sci; 2019; 16(12):1534-1540. PubMed ID: 31839740
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro.
Ziebart T; Pabst A; Klein MO; Kämmerer P; Gauss L; Brüllmann D; Al-Nawas B; Walter C
Clin Oral Investig; 2011 Feb; 15(1):105-11. PubMed ID: 20024592
[TBL] [Abstract][Full Text] [Related]
7. High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis.
Manzano-Moreno FJ; Ramos-Torrecillas J; De Luna-Bertos E; Ruiz C; García-Martínez O
J Craniomaxillofac Surg; 2015 Apr; 43(3):396-401. PubMed ID: 25614214
[TBL] [Abstract][Full Text] [Related]
8. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Vorotnjak M; Boos J; Lanvers-Kaminsky C
Anticancer Drugs; 2004 Sep; 15(8):795-802. PubMed ID: 15494642
[TBL] [Abstract][Full Text] [Related]
9. Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells.
Walter C; Klein MO; Pabst A; Al-Nawas B; Duschner H; Ziebart T
Clin Oral Investig; 2010 Feb; 14(1):35-41. PubMed ID: 19294435
[TBL] [Abstract][Full Text] [Related]
10. The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells.
Açil Y; Möller B; Niehoff P; Rachko K; Gassling V; Wiltfang J; Simon MJ
J Craniomaxillofac Surg; 2012 Dec; 40(8):e229-35. PubMed ID: 22082730
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate Modulation of the Gene Expression of Different Markers Involved in Osteoblast Physiology: Possible Implications in Bisphosphonate-Related Osteonecrosis of the Jaw.
Manzano-Moreno FJ; Ramos-Torrecillas J; Melguizo-Rodríguez L; Illescas-Montes R; Ruiz C; García-Martínez O
Int J Med Sci; 2018; 15(4):359-367. PubMed ID: 29511371
[TBL] [Abstract][Full Text] [Related]
12. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Gralow JR; Barlow WE; Paterson AHG; M'iao JL; Lew DL; Stopeck AT; Hayes DF; Hershman DL; Schubert MM; Clemons M; Van Poznak CH; Dees EC; Ingle JN; Falkson CI; Elias AD; Messino MJ; Margolis JH; Dakhil SR; Chew HK; Dammann KZ; Abrams JS; Livingston RB; Hortobagyi GN
J Natl Cancer Inst; 2020 Jul; 112(7):698-707. PubMed ID: 31693129
[TBL] [Abstract][Full Text] [Related]
13. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
14. The influence of geranylgeraniol on human oral keratinocytes after bisphosphonate treatment: An in vitro study.
Pabst AM; Krüger M; Ziebart T; Jacobs C; Sagheb K; Walter C
J Craniomaxillofac Surg; 2015 Jun; 43(5):688-95. PubMed ID: 25913629
[TBL] [Abstract][Full Text] [Related]
15. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt.
Bezzi M; Hasmim M; Bieler G; Dormond O; Rüegg C
J Biol Chem; 2003 Oct; 278(44):43603-14. PubMed ID: 12933798
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation.
Hagelauer N; Ziebart T; Pabst AM; Walter C
Clin Oral Investig; 2015 Jun; 19(5):1079-91. PubMed ID: 25261400
[TBL] [Abstract][Full Text] [Related]
17. The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells.
Ishtiaq S; Edwards S; Sankaralingam A; Evans BA; Elford C; Frost ML; Fogelman I; Hampson G
Cytokine; 2015 Feb; 71(2):154-60. PubMed ID: 25461393
[TBL] [Abstract][Full Text] [Related]
18. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells.
Açil Y; Arndt ML; Gülses A; Wieker H; Naujokat H; Ayna M; Wiltfang J
J Craniomaxillofac Surg; 2018 Apr; 46(4):538-546. PubMed ID: 29454604
[TBL] [Abstract][Full Text] [Related]
20. Geranylgeraniol - a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw.
Ziebart T; Koch F; Klein MO; Guth J; Adler J; Pabst A; Al-Nawas B; Walter C
Oral Oncol; 2011 Mar; 47(3):195-201. PubMed ID: 21247791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
